China SXT Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of China SXT Pharmaceuticals generated cash of -$1,928,053, which is less than the previous year. Cash used in financing activities reached the amount of -$2,624,428 last year. Net change in cash is therefore -$5,291,291.
Cash Flow
| 2016 | 182.47K | -95.75K | -128.58K |
|---|---|---|---|
| 2017 | 293.04K | -186.30K | -50.56K |
| 2018 | 1.92M | -1.14M | -314.21K |
| 2019 | 239.19K | -610.08K | 9.04M |
| 2020 | 934.24K | -5.49M | 3.02M |
| 2021 | -1.31M | -5.80M | 12.40M |
| 2022 | 268.29K | -46.90K | 1.59M |
| 2023 | -80.75K | -12.30K | 2.94M |
| 2024 | -1.92M | 26.42K | -2.62M |
SXTC Cash Flow Statement (2016 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 17.36M | 15.56M | 13.35M | 7.28M | 9.29M | 657.76K | 65.57K | 11.43K | 55.34K |
Operating activities | |||||||||
Net income | -3.09M | -5.93M | -5.73M | -2.74M | -10.28M | 1.53M | 1.18M | 1.18M | 141.54K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 203.24K | 250.16K | 320.00K | 345.41K | 331.83K | 180.91K | 129.43K | 99.22K | 88.96K |
Stock-based compensation expense | 352.1K | 554.57K | 2.33M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 352.1K | 554.57K | 2.33M | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -321.42K | 912.94K | 831.47K | -519.24K | 104.00K | -1.81M | 384.43K | -942.97K | -1.02M |
Inventories | -190.29K | 408.95K | -180.79K | 38.62K | 39.70K | 177.63K | -274.38K | 384.22K | -57.41K |
Accounts payable | -29.25K | 9.7K | -22.79K | -619.53K | 302.26K | -567.31K | 966.57K | -1.47M | -65.06K |
Cash generated by operating activities | -1.92M | -80.75K | 268.29K | -1.31M | 934.24K | 239.19K | 1.92M | 293.04K | 182.47K |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | -8.84M | -3.59M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -7.06K | -70.68K | -62.49K | -93.04K | -406.65K | -610.08K | -1.05M | -186.30K | -96.99K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.23K |
Cash generated by investing activities | 26.42K | -12.30K | -46.90K | -5.80M | -5.49M | -610.08K | -1.14M | -186.30K | -95.75K |
Financing activities | |||||||||
Common Stock Issued | 0 | 2.19M | 3.11M | 0 | 0 | 6.49M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 1.30M | 4.00M | 2.77M | -124.94K | -1.19M | 69.49K | -314.21K | 0 | -128.58K |
Cash used in financing activities | -2.62M | 2.94M | 1.59M | 12.40M | 3.02M | 9.04M | -314.21K | -50.56K | -128.58K |
Net Change In Cash | -5.29M | 1.79M | 2.21M | 6.07M | -2.00M | 8.63M | 494.68K | 54.13K | -43.90K |
Cash at end of period | 12.07M | 17.36M | 15.56M | 13.35M | 7.28M | 9.29M | 560.25K | 65.57K | 11.43K |
| Data source | Data source | Data source | Data source | Data source | Data source |